[go: up one dir, main page]

HUP0301349A2 - IL-11-tartalmú készítmények - Google Patents

IL-11-tartalmú készítmények

Info

Publication number
HUP0301349A2
HUP0301349A2 HU0301349A HUP0301349A HUP0301349A2 HU P0301349 A2 HUP0301349 A2 HU P0301349A2 HU 0301349 A HU0301349 A HU 0301349A HU P0301349 A HUP0301349 A HU P0301349A HU P0301349 A2 HUP0301349 A2 HU P0301349A2
Authority
HU
Hungary
Prior art keywords
subject
preparations containing
formulations
glycine
prevention
Prior art date
Application number
HU0301349A
Other languages
English (en)
Inventor
Rebecca L. Ingram
Shannon Macmillan
Nicholas W. Warne
Original Assignee
Genetics Institute, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Llc filed Critical Genetics Institute, Llc
Publication of HUP0301349A2 publication Critical patent/HUP0301349A2/hu
Publication of HUP0301349A3 publication Critical patent/HUP0301349A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2073—IL-11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgyát általánosan fogalmazva interleukin-11-et (<IL-11<-et) tartalmazó készítmények képezik. A találmány tárgyát, közelebbrőlIL-11-et, glicint és krioprotektív anyagot tartalmazó készítményekképezik. A találmány szerinti készítmények alkalmasak IL-11-gyelösszefüggő rendellenességek kezelésére és megelőzésére alkalmasgyógyászati készítmények előállítására. Ó
HU0301349A 1999-07-15 2000-07-14 Formulations for il-11 HUP0301349A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35439099A 1999-07-15 1999-07-15
PCT/US2000/019347 WO2001005355A2 (en) 1999-07-15 2000-07-14 Formulations for il-11

Publications (2)

Publication Number Publication Date
HUP0301349A2 true HUP0301349A2 (hu) 2003-08-28
HUP0301349A3 HUP0301349A3 (en) 2005-12-28

Family

ID=23393125

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301349A HUP0301349A3 (en) 1999-07-15 2000-07-14 Formulations for il-11

Country Status (13)

Country Link
US (2) US7033992B2 (hu)
EP (1) EP1368486A4 (hu)
JP (1) JP2003522735A (hu)
AU (1) AU6102600A (hu)
BR (1) BR0012429A (hu)
CA (1) CA2379354A1 (hu)
HU (1) HUP0301349A3 (hu)
IL (2) IL147599A0 (hu)
MX (1) MXPA02000525A (hu)
NO (1) NO20020185L (hu)
NZ (1) NZ516664A (hu)
PL (1) PL360914A1 (hu)
WO (1) WO2001005355A2 (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP2006137678A (ja) * 2004-11-10 2006-06-01 Shionogi & Co Ltd インターロイキン−２組成物
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US20080069796A1 (en) * 2006-07-31 2008-03-20 Kim Jong-Mook Low Dose Treatment with an Interleukin-11 Analog
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
MX2009011367A (es) * 2007-04-26 2010-03-22 Bayer Healthcare Llc Estabilizacion de soluciones liquidas de proteina recombinante para el almacenamiento congelado.
JP5513380B2 (ja) 2007-06-25 2014-06-04 アムジエン・インコーポレーテツド 肝細胞増殖因子に対する特異的結合剤の組成物
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
TWI420342B (zh) * 2010-02-01 2013-12-21 Kinpo Elect Inc 多點受控端之遙控系統、方法與應用於該系統之遙控裝置
CN102319206A (zh) * 2011-09-28 2012-01-18 厦门特宝生物工程股份有限公司 一种稳定的重组人白介素-11水溶液及其制备方法
TWI835773B (zh) * 2018-01-26 2024-03-21 美商建南德克公司 組合物及使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US585962A (en) * 1897-07-06 Charles f
US5215895A (en) 1989-11-22 1993-06-01 Genetics Institute, Inc. Dna encoding a mammalian cytokine, interleukin-11
US5292773A (en) * 1990-02-14 1994-03-08 Hirsch Gerald P Treating aids and HIV infection with methionine
US5371193A (en) * 1990-05-21 1994-12-06 Genetics Institute, Inc. - Legal Affairs Mammalian cytokine, IL-11
EP0546124B2 (en) 1990-08-29 2003-04-23 Genetics Institute, LLC Multidomain hematopoiesis stimulators
US5292646A (en) * 1991-02-06 1994-03-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US5270181A (en) * 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules
US6270757B1 (en) * 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
US5679339A (en) * 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US5885962A (en) * 1996-04-05 1999-03-23 Amgen Inc. Stem cell factor analog compositions and method
JP4382879B2 (ja) * 1996-07-12 2009-12-16 ジェネンテック・インコーポレーテッド ガンマ―ヘレグリン
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11

Also Published As

Publication number Publication date
US7033992B2 (en) 2006-04-25
PL360914A1 (en) 2004-09-20
HUP0301349A3 (en) 2005-12-28
EP1368486A2 (en) 2003-12-10
BR0012429A (pt) 2002-09-17
IL147599A0 (en) 2002-08-14
NO20020185D0 (no) 2002-01-14
JP2003522735A (ja) 2003-07-29
EP1368486A4 (en) 2009-04-01
NO20020185L (no) 2002-03-13
US20060159656A1 (en) 2006-07-20
WO2001005355A3 (en) 2003-10-02
NZ516664A (en) 2003-06-30
IL147599A (en) 2009-09-22
MXPA02000525A (es) 2005-07-01
CA2379354A1 (en) 2001-01-25
AU6102600A (en) 2001-02-05
WO2001005355A2 (en) 2001-01-25
US20040057927A1 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
HUP0301349A2 (hu) IL-11-tartalmú készítmények
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
EE05074B1 (et) Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid, nende kasutamine raviks ja neid sisaldavad farmatseutilised preparaadid
PT1412384E (pt) Formulação estável de glp-1 modificado
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
ATE429210T1 (de) Orale flüssige zusammensetzungen
EE05089B1 (et) Amiidasendatud imidasokinoliinid ja neid sisaldavad farmatseutilised preparaadid
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
DE69620877D1 (de) Arzneimittelformulierungen für il-12
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
MY125766A (en) Flash-melt oral dosage formulation
HUP0302131A2 (hu) Gyógyászati tramadolsók, ezeket tartalmazó gyógyszerkészítmények
ATE329897T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiven substanzen
DE60120648D1 (de) Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
ATE224717T1 (de) Oral anzuwendende arzneizubereitungen enthaltend eine benzhydrylpiperazine und eine zyklodextrin
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
TW200503782A (en) New formulations and use thereof
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
BG106155A (en) Novel derivatives and analogues of galanthamin
HUP0105481A2 (hu) Klaritromicint vagy származékait tartalmazó gyógyászati készítmények és eljárás előállításukra, valamint alkalmazásuk
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE215817T1 (de) Feste miltefosin enthaltende arzneimittel zur oralen verabreichung bei der behandlung von leishmaniasis

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees